<p>SG Americas Securities LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的持股增加了 419.2%。该公司在季度内购买了额外的 93,367 股后，持有该制药公司 115,640 股股票。根据其最近向证券交易委员会提交的文件，SG Americas Securities LLC 在 Vertex Pharmaceuticals 的持股价值为 51,483,000 美元。</p>
<ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
<p>其他几家大型投资者最近也对 VRTX 的持仓进行了调整。美国联合服务汽车协会在第一季度购买了价值 2,933,000 美元的 Vertex Pharmaceuticals 新股份。Lee Johnson Capital Management LLC 在第二季度购买了价值约 721,000 美元的 Vertex Pharmaceuticals 新股份。新泽西州警察和消防员退休系统在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 3.7%。新泽西州警察和消防员退休系统现在拥有 39,035 股该制药公司的股票，价值 17,378,000 美元，此前在该期间内购买了额外的 1,393 股。Bailard Inc. 在第二季度将其在 Vertex Pharmaceuticals 的股份增加了 0.5%。Bailard Inc. 现在拥有 38,147 股该制药公司的股票，价值 16,983,000 美元，此前在该期间内购买了额外的 200 股。最后，SteelPeak Wealth LLC 在第二季度收购了价值约 10,059,000 美元的 Vertex Pharmaceuticals 新股份。机构投资者和对冲基金持有该公司 90.96% 的股票。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<h2>Vertex Pharmaceuticals 股票表现</h2>
<p>VRTX 股票在周五开盘价为 437.15 美元。该公司的市值为 1,109.1 亿美元，市盈率为 31.25，贝塔值为 0.36。Vertex Pharmaceuticals Incorporated 的 52 周低点为 362.50 美元，52 周高点为 519.68 美元。该公司的 50 日移动平均价格为 408.04 美元，200 日移动平均价格为 427.84 美元。</p>
<ul>
<li>2025 年最佳生物技术股票</li>
</ul>
<p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近在 11 月 3 日星期一发布了季度财报。该制药公司报告季度每股收益 (EPS) 为 4.80 美元，超出分析师一致预期的 4.58 美元，超出幅度为 0.22 美元。Vertex Pharmaceuticals 的股本回报率为 23.91%，净利润率为 31.86%。该公司在季度内的收入为 30.8 亿美元，而一致预期为 30.5 亿美元。去年同期，该公司每股收益为 4.38 美元。Vertex Pharmaceuticals 的季度收入同比增长 11.0%。Vertex Pharmaceuticals 已设定其 2025 财年的每股收益指导。分析师预测 Vertex Pharmaceuticals Incorporated 今年将发布 15.63 美元的每股收益。</p>
<h2>分析师设定新目标价</h2>
<p>几位研究分析师对 VRTX 股票发布了报告。瑞银集团在 11 月 7 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 553.00 美元下调至 546.00 美元，并对该股票给予 &#34;买入&#34; 评级。摩根士丹利在 10 月 10 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 439.00 美元下调至 438.00 美元，并对该公司给予 &#34;持平&#34; 评级。华尔街 Zen 在 8 月 22 日的研究报告中将 Vertex Pharmaceuticals 的评级从 &#34;强烈买入&#34; 下调至 &#34;买入&#34;。Stifel Nicolaus 在 11 月 4 日的报告中将 Vertex Pharmaceuticals 的目标价从 455.00 美元下调至 445.00 美元，并对该公司给予 &#34;持有&#34; 评级。最后，Cantor Fitzgerald 在 8 月 5 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 535.00 美元下调至 485.00 美元，并对该股票给予 &#34;超配&#34; 评级。两位研究分析师对该股票给予 &#34;强烈买入&#34; 评级，十六位给予 &#34;买入&#34; 评级，十一位给予 &#34;持有&#34; 评级。根据 MarketBeat.com 的数据，Vertex Pharmaceuticals 的平均评级为 &#34;适度买入&#34;，共识目标价为 491.95 美元。</p>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p><strong>阅读我们最新的 Vertex Pharmaceuticals 股票分析</strong></p>
<h2>Vertex Pharmaceuticals 公司简介</h2>
<p>(免费报告)</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化 (CF) 的疗法。它为至少 2 岁或以上的 F508del 突变患者提供 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者提供 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者提供 ORKAMBI；以及为 1 岁或以上的 CF 患者提供 KALYDECO。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Vertex Pharmaceuticals</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>MarketBeat 周回顾 – 11/10 - 11/14</li>
<li>投资中的下调意味着什么？</li>
<li>这三家被低估的科技巨头准备反弹吗？</li>
<li>2025 年有潜力上涨的两只 CRM 平台股票</li>
<li>如果你等待下跌，Micron Technology 可能会让你错过机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>SG Americas Securities LLC 在第二季度显著增加了对 Vertex Pharmaceuticals 的持股，增幅达到 419.2%，目前持有 115,640 股，市值为 5148 万美元。其他投资者也调整了在 Vertex 的持仓。该公司的股票开盘价为 437.15 美元，市值为 1109.1 亿美元。分析师们对该股的评级意见不一，普遍目标价为 491.95 美元。Vertex 报告第三季度每股收益为 4.80 美元，超出预期，收入同比增长 11%</p>

<p>SG Americas Securities LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 419.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 115,640 shares of the pharmaceutical company's stock after buying an additional 93,367 shares during the quarter. SG Americas Securities LLC's holdings in Vertex Pharmaceuticals were worth $51,483,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>SG Americas Securities LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免费报告) 的持股增加了 419.2%。该公司在季度内购买了额外的 93,367 股后，持有该制药公司 115,640 股股票。根据其最近向证券交易委员会提交的文件，SG Americas Securities LLC 在 Vertex Pharmaceuticals 的持股价值为 51,483,000 美元。</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
</div><p>Several other large investors also recently made changes to their positions in VRTX. United Services Automobile Association bought a new stake in Vertex Pharmaceuticals during the first quarter valued at $2,933,000. Lee Johnson Capital Management LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $721,000. Police &amp; Firemen s Retirement System of New Jersey increased its holdings in shares of Vertex Pharmaceuticals by 3.7% during the second quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company's stock valued at $17,378,000 after purchasing an additional 1,393 shares during the period. Bailard Inc. increased its stake in Vertex Pharmaceuticals by 0.5% during the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company's stock valued at $16,983,000 after buying an additional 200 shares during the period. Finally, SteelPeak Wealth LLC acquired a new stake in Vertex Pharmaceuticals in the second quarter worth approximately $10,059,000. Institutional investors and hedge funds own 90.96% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也对 VRTX 的持仓进行了调整。美国联合服务汽车协会在第一季度购买了价值 2,933,000 美元的 Vertex Pharmaceuticals 新股份。Lee Johnson Capital Management LLC 在第二季度购买了价值约 721,000 美元的 Vertex Pharmaceuticals 新股份。新泽西州警察和消防员退休系统在第二季度将其在 Vertex Pharmaceuticals 的持股增加了 3.7%。新泽西州警察和消防员退休系统现在拥有 39,035 股该制药公司的股票，价值 17,378,000 美元，此前在该期间内购买了额外的 1,393 股。Bailard Inc. 在第二季度将其在 Vertex Pharmaceuticals 的股份增加了 0.5%。Bailard Inc. 现在拥有 38,147 股该制药公司的股票，价值 16,983,000 美元，此前在该期间内购买了额外的 200 股。最后，SteelPeak Wealth LLC 在第二季度收购了价值约 10,059,000 美元的 Vertex Pharmaceuticals 新股份。机构投资者和对冲基金持有该公司 90.96% 的股票。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Vertex Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票表现</h2>
</div><p>Shares of VRTX stock opened at $437.15 on Friday. The company has a market capitalization of $110.91 billion, a P/E ratio of 31.25 and a beta of 0.36. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68. The company's 50 day moving average price is $408.04 and its two-hundred day moving average price is $427.84.</p>
<div class="lb-trans"><p>VRTX 股票在周五开盘价为 437.15 美元。该公司的市值为 1,109.1 亿美元，市盈率为 31.25，贝塔值为 0.36。Vertex Pharmaceuticals Incorporated 的 52 周低点为 362.50 美元，52 周高点为 519.68 美元。该公司的 50 日移动平均价格为 408.04 美元，200 日移动平均价格为 427.84 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技术股票</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the company earned $4.38 earnings per share. Vertex Pharmaceuticals's quarterly revenue was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals (NASDAQ:VRTX - 获取免费报告) 最近在 11 月 3 日星期一发布了季度财报。该制药公司报告季度每股收益 (EPS) 为 4.80 美元，超出分析师一致预期的 4.58 美元，超出幅度为 0.22 美元。Vertex Pharmaceuticals 的股本回报率为 23.91%，净利润率为 31.86%。该公司在季度内的收入为 30.8 亿美元，而一致预期为 30.5 亿美元。去年同期，该公司每股收益为 4.38 美元。Vertex Pharmaceuticals 的季度收入同比增长 11.0%。Vertex Pharmaceuticals 已设定其 2025 财年的每股收益指导。分析师预测 Vertex Pharmaceuticals Incorporated 今年将发布 15.63 美元的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several research analysts have issued reports on VRTX shares. UBS Group decreased their price target on shares of Vertex Pharmaceuticals from $553.00 to $546.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Morgan Stanley reduced their price objective on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an &#34;equal weight&#34; rating for the company in a research note on Friday, October 10th. Wall Street Zen downgraded Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, August 22nd. Stifel Nicolaus cut their price target on Vertex Pharmaceuticals from $455.00 to $445.00 and set a &#34;hold&#34; rating for the company in a report on Tuesday, November 4th. Finally, Cantor Fitzgerald decreased their price target on Vertex Pharmaceuticals from $535.00 to $485.00 and set an &#34;overweight&#34; rating on the stock in a research note on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $491.95.</p>
<div class="lb-trans"><p>几位研究分析师对 VRTX 股票发布了报告。瑞银集团在 11 月 7 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 553.00 美元下调至 546.00 美元，并对该股票给予 &#34;买入&#34; 评级。摩根士丹利在 10 月 10 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 439.00 美元下调至 438.00 美元，并对该公司给予 &#34;持平&#34; 评级。华尔街 Zen 在 8 月 22 日的研究报告中将 Vertex Pharmaceuticals 的评级从 &#34;强烈买入&#34; 下调至 &#34;买入&#34;。Stifel Nicolaus 在 11 月 4 日的报告中将 Vertex Pharmaceuticals 的目标价从 455.00 美元下调至 445.00 美元，并对该公司给予 &#34;持有&#34; 评级。最后，Cantor Fitzgerald 在 8 月 5 日的研究报告中将 Vertex Pharmaceuticals 的目标价从 535.00 美元下调至 485.00 美元，并对该股票给予 &#34;超配&#34; 评级。两位研究分析师对该股票给予 &#34;强烈买入&#34; 评级，十六位给予 &#34;买入&#34; 评级，十一位给予 &#34;持有&#34; 评级。根据 MarketBeat.com 的数据，Vertex Pharmaceuticals 的平均评级为 &#34;适度买入&#34;，共识目标价为 491.95 美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 Vertex Pharmaceuticals 股票分析</strong></p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化 (CF) 的疗法。它为至少 2 岁或以上的 F508del 突变患者提供 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者提供 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者提供 ORKAMBI；以及为 1 岁或以上的 CF 患者提供 KALYDECO。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>MarketBeat Week in Review – 11/10 - 11/14</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Vertex Pharmaceuticals</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>MarketBeat 周回顾 – 11/10 - 11/14</li>
<li>投资中的下调意味着什么？</li>
<li>这三家被低估的科技巨头准备反弹吗？</li>
<li>2025 年有潜力上涨的两只 CRM 平台股票</li>
<li>如果你等待下跌，Micron Technology 可能会让你错过机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

SG Americas Securities LLC 增加了在福泰制药公司 $VRTX 的持仓